Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
other · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28829863.
- Also identified by DOI 10.1001/jama.2017.9924 and PMC identifier 5817484.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
Medical subject headings
- Antibodies, Monoclonal
- Anticholesteremic Agents
- Cholesterol, LDL
- Hypercholesterolemia
- PCSK9 Inhibitors